SEARCH

SEARCH BY CITATION

References

  • 1
    Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rossenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin dependent diabetes mellitus. J Clin Invest 1995;96:5207.
  • 2
    Morgan C, Jenkins-Jones S, Currie C, Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. J Clin Endocrinol Metab 2012;97:325160.
  • 3
    Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996;45:6239.
  • 4
    Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:8216.
  • 5
    Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu P, Zborowski JV, Remsberg KE, et al. Evidence for the association between polycystic ovary syndrome and premature carotid atherosclerosis in middle aged women. Arterioscler Thromb Vasc Biol 2000;20:241421.
  • 6
    Sprung VS, Atkinson G, Cuthbertson DJ, Pugh CJ, Aziz N, Green DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. Clin Endocrinol 2013;78:43846.
  • 7
    Nácul AP, Andrade CD, Schwarz P, De Bittencourt PI Jr, Spritizer PM. Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity. Eur J Obstet Gynecol Reprod Biol 2007;133:1916.
  • 8
    Karadeniz M, Erdoğan M, Ayhan Z, Yalcin M, Olukman M, Centikalp S, et al. Effect of G2706A and G1051A polymorphisms of the ABCA1 gene on the lipid, oxidative stress and homocystein levels in Turkish patients with polycystic ovary syndrome. Lipids Health Dis 2011;10:193.
  • 9
    Baskol G, Aygen E, Erdem F, Caniklioğlu A, Narin F, Sahin Y, et al. Assessment of paraoxonase 1, xanthine oxidase and glutathione peroxidise activities, nitric oxide and thiol levels in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2012;91:32630.
  • 10
    Türkçüoğlu I, Engin-Üstün Y, Turan F, Kali Z, Karabulut AB, Meydanli M, et al. Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome. Gynecol Endocrinol 2011;27:60914.
  • 11
    Kuşçu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2009;88:61217.
  • 12
    Erdogan M, Karadeniz M, Berdeli A, Alper G, Cağlayan O, Yilmaz C. The relationship of the interleukin-6 174G>C gene polymorphism with oxidative stress markers in Turkish polycystic ovary syndrome patients. J Endocrinol Invest 2008;31:6249.
  • 13
    Karadeniz M, Erdoğan M, Tamsel S, Zengi A, Alper GE, Cağlayan O, et al. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistance. Exp Clin Endocrinol Diabetes 2008;116:2315.
  • 14
    Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M. Escobar-Morreake HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 2013;19:26888.
  • 15
    Watson S, Blundell HL, Evans WD, Griffiths H, Newcombe RG, Rees DA. Can abdominal bioelectrical impedance refine the determination of visceral fat from waist circumference? Physiol Meas 2009;30:N538.
  • 16
    Pinder AG, Khalatbari A, Ingram TE, James PE. The measurement of nitric oxide and its metabolites in biological samples by ozone-based chemiluminescence. Methods Mol Biol 2009;476:1027.
  • 17
    Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995;44:10548.
  • 18
    Prior RL, Hoang H, Gu L, Wu X, Bacchiocca M, Howard L, et al. Assays for hydrophilic and lipophilic antioxidant capacity (oxygen radical absorbance capacity (ORAC(FL))) of plasma and other biological and food samples. J Agric Food Chem 2003;51:32739.
  • 19
    Anderson RA, Evans ML, Ellis GR, Graham K, Morris K, Jackson SK, et al. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 2001;154:47583.
  • 20
    Ingram TE, Fraser AG, Bleasdale RA, Ellins EA, Margulescu AD, Halcox JP. Low-dose sodium nitrite attenuates myocardial ischemia and vascular ischemia–reperfusion injury in human models. J Am Coll Cardiol 2013;61:253441.
  • 21
    Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005;90:25459.
  • 22
    Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O, et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 2003;35:7906.
  • 23
    Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Freelisch M, et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci USA 2001;98:1281419.
  • 24
    Bryan NS. Nitrite in nitric oxide biology: cause or consequence? A systems-based review. Free Radic Biol Med 2006;41:691701.
  • 25
    Bailey DM, Davies B, Young IS, Jackson MJ, Davison GW, Isaacson R, et al. EPR spectroscopic detection of free radical outflow from an isolated muscle bed in exercising humans. J Appl Physiol 2003;94:171418.
  • 26
    Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:87580.
  • 27
    Fenkci V, Fenkci S, Yilmazer M, Sertesser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80:1237.
  • 28
    Blair SA, Kyaw-Tun T, Young IS, Niamh OA, Gibney J, McEneny J. Oxidative stress and inflammation in lean and obese subjects with polycystic ovary syndrome. J Reprod Med 2013;58:10714.
  • 29
    Kurdoglu Z, Ozkol H, Tuluce Y, Koyuncu I. Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. J Endocrinol Invest 2012;35:31721.
  • 30
    Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, Petakov M, et al. Oxidized low-density lipoprotein concentration—early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol 2006;155:1316.
  • 31
    Glintborg D, Hojlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 2008;31:32834.
  • 32
    Demirel F, Bideci A, Cinaz P, Camurdan MO, Biberoğlu G, Yesilkaya E, et al. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol 2007;67:12934.